4-[(4-boronophenyl)methyl]thiomorpholine 1,1-dioxide | 747413-23-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(4-boronophenyl)methyl]thiomorpholine 1,1-dioxide
• 英文别名: (4-((1,1-Dioxidothiomorpholino)methyl)phenyl)boronic acid；[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]boronic acid
• CAS: 747413-23-6
• 化学式: C₁₁H₁₆BNO₄S
• 分子量: 269.129
• InChiKey: CIZHHURYUJSTKL-UHFFFAOYSA-N

物化性质

• 沸点：
  523.7±60.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(4-boronophenyl)methyl]thiomorpholine 1,1-dioxide 、 5-溴-[1,2,4]三噻唑[1,5-A]吡啶-2-胺 在 4-(4-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzyl)thiomorpholine-1,1-dioxide 、 silica gel 作用下， 以5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-amine (490 mg, 79%) was isolated as a beige foam的产率得到4-(4-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzyl)thiomorpholine-1,1-dioxide
  参考文献：
  名称：

  Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives

  摘要：

  本申请涉及通式I的化合物及其盐，其中X、R1A、R1B、R2、R3、R4和R5的定义如本文所述。该申请还涉及治疗过度增殖性疾病或疾病的组合物和方法。

  公开号：

  US20100311693A1
• 作为产物：
  描述：

  4-(aminomethyl)phenylboronic acid hydrochloride 、 二乙烯基砜 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 4-[(4-boronophenyl)methyl]thiomorpholine 1,1-dioxide
  参考文献：
  名称：

  4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

  摘要：

  Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.

  DOI：

  10.1021/jm701018h

文献信息

• 芳香杂环酰胺类化合物及其制备方法和医药用途
  申请人：南京柯菲平盛辉制药有限公司

  公开号：CN114075188A

  公开（公告）日：2022-02-22

  本发明公开一种芳香杂环酰胺类化合物及其制备方法和医药用途，涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药，本发明还提供本发明式I的化合物在用于制备预防或治疗JAK激酶相关疾病药物中的用途。
• PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
  申请人：Breslin Henry J.

  公开号：US20120028919A1

  公开（公告）日：2012-02-02

  The present invention provides a compound of formula I or a salt form thereof, wherein Q 1 , Q 2 , Q 3 , and Q 4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了公式I或其盐形式的化合物，其中Q1、Q2、Q3和Q4的定义如本文所述。公式I的化合物具有ALK和/或JAK2抑制活性，可用于治疗增生性疾病。
• Pyrrolotriazines as ALK and JAK2 inhibitors
  申请人：Breslin Henry J.

  公开号：US08471005B2

  公开（公告）日：2013-06-25

  The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了公式I或其盐形式的化合物，其中Q1、Q2、Q3和Q4的定义如本文所述。公式I的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
  申请人：Curry Matthew A.

  公开号：US08501936B2

  公开（公告）日：2013-08-06

  This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

  本申请涉及一般式I的化合物及其盐，其中X、R1A、R1B、R2、R3、R4和R5的定义如本文所述。本申请还涉及治疗过度增殖性疾病或障碍的组合物和方法。
• [EN] PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATION DE DÉRIVÉS DE 1,2,4-TRIAZOLO[1,5A]PYRIDINE
  申请人：CEPHALON INC

  公开号：WO2010141796A3

  公开（公告）日：2012-02-16